$38.3 Million is the total value of Yu Fan's 5 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AVIR | Sell | ATEA PHARMACEUTICALS INC | $18,525,000 | -50.7% | 300,000 | -66.7% | 48.35% | -21.1% |
| LUNG | PULMONX CORP | $13,861,000 | -33.7% | 303,030 | 0.0% | 36.18% | +6.2% | |
| ABGI | New | ABG ACQUISITION CORP I | $4,958,000 | – | 501,300 | +100.0% | 12.94% | – |
| AGLE | Sell | AEGLEA BIOTHERAPEUTICS INC | $887,000 | -66.5% | 112,044 | -66.7% | 2.32% | -46.3% |
| Sell | DIFFUSION PHARMACEUTICALS IN | $82,000 | -61.5% | 89,848 | -66.7% | 0.21% | -38.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2021-09-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CASTLE BIOSCIENCES INC | 12 | Q3 2023 | 24.7% |
| ABG ACQUISITION CORP I | 8 | Q4 2022 | 83.9% |
| SONENDO INC | 8 | Q3 2023 | 60.4% |
| PRENETICS GLOBAL LTD | 6 | Q3 2023 | 1.9% |
| DIFFUSION PHARMACEUTICALS IN | 6 | Q1 2022 | 0.8% |
| CASTLE BIOSCIENCES INC | 5 | Q2 2023 | 25.8% |
| APEXIGEN INC | 4 | Q2 2023 | 14.8% |
| ATEA PHARMACEUTICALS INC | 3 | Q2 2021 | 61.3% |
| PULMONX CORP | 2 | Q1 2021 | 36.2% |
| SAGIMET BIOSCIENCES INC | 1 | Q3 2023 | 35.7% |
View Yu Fan's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Pulmonx Corp | February 11, 2022 | 31,903 | 0.1% |
View Yu Fan's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-21 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-03-15 |
| 4 | 2023-03-03 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View Yu Fan's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.